Adiponectin Levels Are Elevated in Patients With Pulmonary Arterial Hypertension

In addition to insulin‐sensitizing effects, adiponectin influences several mechanisms involved in pulmonary arterial hypertension (PAH) pathobiology. Insulin resistance has been associated with PAH, and elevated adiponectin levels have been described in left heart failure (HF) as a response to the increased metabolic stress. No studies have been performed in right HF or PAH patients.

[1]  A. Garnier,et al.  Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure , 2013, Heart Failure Reviews.

[2]  J. Jordan,et al.  Atrial Natriuretic Peptide and Adiponectin Interactions in Man , 2012, PloS one.

[3]  D. Mancini,et al.  Adipose Tissue Inflammation and Adiponectin Resistance in Patients With Advanced Heart Failure: Correction After Ventricular Assist Device Implantation , 2012, Circulation. Heart failure.

[4]  A. Leite-Moreira,et al.  Current pathophysiological concepts and management of pulmonary hypertension. , 2012, International journal of cardiology.

[5]  M. Humbert,et al.  Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension , 2012, European Respiratory Journal.

[6]  E. Disse,et al.  How can we measure insulin sensitivity/resistance? , 2011, Diabetes & metabolism.

[7]  H. Yamawaki.  Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. , 2011, Biological & pharmaceutical bulletin.

[8]  E. K. Weir,et al.  Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.

[9]  T. Rice,et al.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  S. Kihara,et al.  Determinants of adiponectin levels in patients with chronic systolic heart failure. , 2010, The American journal of cardiology.

[11]  S. Anker,et al.  Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study). , 2010, The American journal of cardiology.

[12]  H. Champion,et al.  Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography , 2009, International journal of clinical practice. Supplement.

[13]  D. Dwyer,et al.  Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[14]  T. Funahashi,et al.  Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. , 2009, Journal of the American College of Cardiology.

[15]  M. Harmsen,et al.  Pleiotropism of adiponectin: inflammation, neovascularization, and fibrosis. , 2009, Circulation research.

[16]  T. Nawrot,et al.  C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[17]  Kohtaro Abe,et al.  The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. , 2009, Chest.

[18]  P. Libby,et al.  Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. , 2009, American journal of respiratory cell and molecular biology.

[19]  G. Hansmann,et al.  Insulin resistance in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[20]  Hideki Katagiri,et al.  Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals , 2007, Circulation research.

[21]  Ahmad Y. Sheikh,et al.  Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation , 2007 .

[22]  Herbert Tilg,et al.  Adipocytokines: mediators linking adipose tissue, inflammation and immunity , 2006, Nature Reviews Immunology.

[23]  Shinji Kihara,et al.  Adiponectin: a key adipocytokine in metabolic syndrome. , 2006, Clinical science.

[24]  P. Ponikowski,et al.  Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. , 2005, Journal of the American College of Cardiology.

[25]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[26]  T. Funahashi,et al.  Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. , 2005, Cardiovascular research.

[27]  S. Verma,et al.  Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction , 2003, Circulation.

[28]  M. Yokoyama,et al.  Leptin stimulates rat aortic smooth muscle cell proliferation and migration. , 2001, The Kobe journal of medical sciences.

[29]  J. Cauley,et al.  Measurement of fat mass using DEXA: a validation study in elderly adults. , 2000, Journal of applied physiology.

[30]  Ahmad Y. Sheikh,et al.  Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. , 2007, Circulation.

[31]  Human Experimentation: Code of Ethics of the World Medical Association (Declaration of Helsinki). , 1964, Canadian Medical Association journal.

[32]  P. P. Rickham.  HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI. , 1964, British medical journal.